We are live on
!
Find out more
CUAMC
China Universal Asset Management Company Portfolio holdings
AUM
$1.67B
1-Year Est. Return
89%
This Fund
S&P 500
This Quarter
Est. Return
+16%
1 Year Est. Return
+89%
3 Year Est. Return
+264.17%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$324M
AUM Growth
+$28.5M
(+9.6%)
Cap. Flow
-$2.62M
Cap. Flow
% of AUM
-0.81%
Top 10 Holdings %
Top 10 Hldgs %
32.96%
Holding
465
New
18
Increased
159
Reduced
243
Closed
13
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vanguard World Funds Extended Duration ETF
EDV
|
+$3.29M |
| 2 |
Alnylam Pharmaceuticals
ALNY
|
+$1.96M |
| 3 |
Apple
AAPL
|
+$1.92M |
| 4 |
Vaxcyte
PCVX
|
+$1.9M |
| 5 |
Meta Platforms (Facebook)
META
|
+$1.81M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iQIYI
IQ
|
+$5.11M |
| 2 |
Amazon
AMZN
|
+$4.12M |
| 3 |
Airbnb
ABNB
|
+$2.92M |
| 4 |
Analog Devices
ADI
|
+$2.79M |
| 5 |
KE Holdings
BEKE
|
+$2.12M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 41.8% |
| 2 | Consumer Discretionary | 21.38% |
| 3 | Healthcare | 19.26% |
| 4 | Communication Services | 6.74% |
| 5 | Financials | 4.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
276
Aurinia Pharmaceuticals
AUPH
$2.06B
| $18.1K | 0.01% |
1,875
-57
| -3% | -$592 |
|
|
ETNB
277
DELISTED
89bio
ETNB
| $18.1K | 0.01% |
955
+270
| +39% | +$4.74K |
|
278
Recursion Pharmaceuticals
RXRX
$1.76B
| $18.1K | 0.01% |
2,420
-65
| -3% | -$455 |
|
279
IDEAYA Biosciences
IDYA
$3.56B
| $17.6K | 0.01% |
751
+99
| +15% | +$2.04K |
|
280
Replimune Group
REPL
$1.28B
| $17.6K | 0.01% |
757
-11
| -1% | -$215 |
|
281
BioCryst Pharmaceuticals
BCRX
$2.71B
| $17.4K | 0.01% |
2,477
-77
| -3% | -$618 |
|
282
Arvinas
ARVN
$580M
| $17.4K | 0.01% |
700
-22
| -3% | -$566 |
|
283
Kymera Therapeutics
KYMR
$9.48B
| $16.7K | 0.01% |
725
-23
| -3% | -$659 |
|
284
Ligand Pharmaceuticals
LGND
$5.85B
| $16.3K | 0.01% |
226
-5
| -2% | -$375 |
|
285
Repligen
RGEN
$9.35B
| $16.3K | 0.01% |
115
-2,841
| -96% | -$456K |
|
|
MRUS
286
DELISTED
Merus
MRUS
| $16.1K | 0.01% |
610
-18
| -3% | -$394 |
|
287
ImmunityBio
IBRX
$8.2B
| $15.9K | ﹤0.01% |
5,715
+100
| +2% | +$283 |
|
288
Keros Therapeutics
KROS
$222M
| $15.6K | ﹤0.01% |
388
+15
| +4% | +$658 |
|
289
Twist Bioscience
TWST
$7.85B
| $15.3K | ﹤0.01% |
749
-21
| -3% | -$315 |
|
|
VERV
290
DELISTED
Verve Therapeutics
VERV
| $15.2K | ﹤0.01% |
812
-23
| -3% | -$383 |
|
291
Travere Therapeutics
TVTX
$5.86B
| $15K | ﹤0.01% |
978
+101
| +12% | +$1.84K |
|
292
Sana Biotechnology
SANA
$1.13B
| $15K | ﹤0.01% |
2,510
-74
| -3% | -$426 |
|
|
INBX
293
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $14.8K | ﹤0.01% |
572
-18
| -3% | -$420 |
|
|
DCPH
294
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $14.5K | ﹤0.01% |
1,029
| – | – |
|
295
ANI Pharmaceuticals
ANIP
$1.73B
| $14.3K | ﹤0.01% |
265
+29
| +12% | +$1.28K |
|
296
Lucid Motors
LCID
$2.58B
| $14.3K | ﹤0.01% |
207
+152
| +276% | +$10.8K |
|
297
MannKind Corp
MNKD
$1.24B
| $14.1K | ﹤0.01% |
3,464
-111
| -3% | -$463 |
|
298
Pliant Therapeutics
PLRX
$66.3M
| $14K | ﹤0.01% |
775
+2
| +0.3% | +$47 |
|
|
CBAY
299
DELISTED
Cymabay Therapeutics
CBAY
| $14K | ﹤0.01% |
1,278
-4
| -0.3% | -$37 |
|
|
AVDL
300
DELISTED
Avadel Pharmaceuticals
AVDL
| $13.9K | ﹤0.01% |
844
-7
| -0.8% | -$91 |
|
Similar funds
HA
JPM
CPO
LCI
GWM
JIP
RMC
GACM
China Universal Asset Management Company's Q2 2023 Portfolio in Review
As of Q2 2023, China Universal Asset Management Company held 465 positions worth $324M, up 9.6% from $295M the previous quarter. Its ten largest holdings account for 33% of the portfolio.
China Universal Asset Management Company's Q2 2023 filing shows 18 new, 159 increased, 243 reduced and 13 closed positions. Its largest new stake was Vanguard World Funds Extended Duration ETF: 37,709 shares worth $3.28M. The largest sale was iQIYI, an estimated $5.11M.
By sector, the portfolio is most concentrated in Technology at 42% of assets, up from 38% a quarter earlier, followed by Consumer Discretionary and Healthcare.
- China Universal Asset Management Company's largest Q2 2023 buy was Vanguard World Funds Extended Duration ETF: 37,709 shares worth $3.28M.
- China Universal Asset Management Company added most to Alnylam Pharmaceuticals in Q2 2023, an estimated $1.96M increase.
- China Universal Asset Management Company's biggest Q2 2023 reduction was iQIYI, cutting an estimated $5.11M.
- China Universal Asset Management Company fully exited Block Inc in Q2 2023, selling an estimated $1.35M.
- China Universal Asset Management Company's ten largest holdings make up 33% of its $324M portfolio in Q2 2023.
- China Universal Asset Management Company opened 18 new positions and closed 13 in Q2 2023.
- China Universal Asset Management Company's portfolio value rose 9.6% quarter-over-quarter to $324M.
Based on China Universal Asset Management Company's 13F filing for Q2 2023, filed 28 Jul 2023.